Dr. John Cush RheumNow
5 months 3 weeks ago
FDA sent a complete response letter to AstraZeneca on their application (BLA) for anifrolumabs (Saphnelo) subcutaneous use in SLE. Despite a positive TULIP-SC trial & EU approval of SC-anifrolumab, FDA & sponsor still have to work things out. CRL reasons are unknown https://t.co/3dNwEyolrj
Dr. John Cush RheumNow
5 months 3 weeks ago
Congratulations to Anca Dinu Askanase, MD, MPH, who has been appointed Chair of the Department of Medicine and Chief of the Division of Rheumatology at Hospital for Special Surgery https://t.co/L5mbFloLpK https://t.co/gsZm9Is159
The FDA has requested that Amgen voluntarily withdraw avacopan (Tavneos), a treatment for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, but the company said it has no plans to pull the drug from the market.
The American College of Rheumatology (ACR) today applauded the recent passage of the Congressional CY 26 funding package that includes several important provisions, including extending Medicare telehealth payment flexibilities, improving transparency in pharmacy benefit management (PBM) practices, and advancing arthritis research.
Dr. John Cush RheumNow
5 months 3 weeks ago
Hiring, Onboarding and Training APPs
Tuesday Night Rheumatology: Hiring, Onboarding and Training APPs. Visit our Mission APP: Partners in Care site for more APP-focused articles and videos.
https://t.co/CGrXSCrp9n https://t.co/wYkb6C1IEW
Dr. John Cush RheumNow
5 months 3 weeks ago
Which Fibromyalgia Drugs are Cost-Effective?
A cost-effectiveness analysis compared FDA approved fibromyalgia (FM) drugs (pregabalin, duloxetine, milnacipran) with amitriptyline and found duloxetine was the preferred strategy across perspectives.
https://t.co/5NZeYquGxs https://t.co/rhcwH2yLEm
Dr. John Cush RheumNow
5 months 3 weeks ago
Take home points from his presentation. Dr. David Karp lecturing at UTSW @drdavidkarp @utswrheum https://t.co/kDFrGi7iXt
Dr. John Cush RheumNow
5 months 3 weeks ago
NEXT STEPS: Karp and investigators are engaged in the MONA LISA study - Using smile Data and biospeciments – they intend to look for biomarkers that may better predict the future development of SLE Dr. David Karp lecturing at UTSW @drdavidkarp @utswrheum https://t.co/acZD1kmNhq
Dr. John Cush RheumNow
5 months 3 weeks ago
The challenge may be that lupus has multiple endotypes with variable rates of progression/trajectories. Can you Prevent SLE? Dr. David Karp lecturing at UTSW @drdavidkarp @utswrheum https://t.co/BA4KRKebIv
Dr. John Cush RheumNow
5 months 3 weeks ago
SMILE enrollment hampered by COVID - yet failed to show a protective effect for HCQ in preventing SLE. Can you Prevent SLE? Dr. David Karp lecturing at UTSW @drdavidkarp @utswrheum https://t.co/GImHpycbgO
Dr. John Cush RheumNow
5 months 3 weeks ago
REcently published SMILE study looked at the potential of HCQ (vs PBO) to prevent SLE in at risk people. Had to be ANA+ and 1-2 SLICC criteria at entry. Can you Prevent SLE? Dr. David Karp lecturing at UTSW @drdavidkarp @utswrheum https://t.co/4FY0kOLdRT
Dr. John Cush RheumNow
5 months 3 weeks ago
Factors that may augment future development of SLE - includes Vitamin D levels, poor sleep, EBV reactivation & social determinants of health. Can you Prevent SLE? Dr. David Karp lecturing at UTSW @drdavidkarp @utswrheum https://t.co/e3TKATcxXB
Dr. John Cush RheumNow
5 months 3 weeks ago
Only a subset of incomplete lupus (ILE) will progress to SLE - betw 1 in 10 and 1 in 5. Can you Prevent SLE? Dr. David Karp lecturing at UTSW @drdavidkarp @utswrheum https://t.co/oo40Dumk4I
Dr. John Cush RheumNow
5 months 3 weeks ago
Can you Prevent SLE? Dr. David Karp lecturing at UTSW Showing that autoantibodies exist long before the onset of SLE @drdavidkarp @utswrheum https://t.co/zPAYbSlIBS
